Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Feld

Showing results (391-400 of 451) with videos related to

Pageof 46
Sort By:
Hepatology (Baltimore, Md.)|November 4, 2025
AASLD/IDSA Practice Guideline on treatment of chronic hepatitis BMarc G Ghany, Calvin Q Pan, Anna S Lok, et al.
BMJ Open Gastroenterology|April 19, 2024
Progression of the FIB-4 index among patients with chronic HCV infection and early liver diseaseLisette A P Krassenburg, Raoel Maan, Amy Puenpatom, et al.
Journal of Hepatology|May 23, 2021
Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infectionGail V Matthews, Sanjay Bhagani, Marc Van der Valk, et al.
Hepatology (Baltimore, Md.)|November 7, 2021
Incidence and prediction of HBsAg seroclearance in a prospective multi-ethnic HBeAg-negative chronic hepatitis B cohortNorah A Terrault, Abdus S Wahed, Jordan J Feld, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 16, 2025
Peginterferon λ for the treatment of patients admitted to hospital with COVID-19: a phase 2, placebo-controlled randomized trialChristopher Kandel, Mia J Biondi, Mark Gillrie, et al.
Hepatology Communications|December 3, 2025
Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trialSanam Tabataba Vakili, Grishma Hirode, Atif Zahoor, et al.
The Journal of Infectious Diseases|July 21, 2021
The Inflammatory Cytokine Profile Associated With Liver Damage Is Broader and Stronger in Patients With Chronic Hepatitis B Compared to Patients With Acute Hepatitis BAlexandra Johnson Valiente, Kin Seng Liem, Kathleen B Schwarz, et al.
Journal of Viral Hepatitis|April 12, 2019
Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis BAdrian M Di Bisceglie, Wendy C King, Mauricio Lisker-Melman, et al.
Gut|November 6, 2025
HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER)Edo J Dongelmans, Lesley A Patmore, Seng Gee Lim, et al.
Journal of Hepatology|October 27, 2019
Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trialGregory J Dore, Jordan J Feld, Alex Thompson, et al.
Pageof 46

Showing results (391-400 of 451) with videos related to

Sort By:
Pageof 46
Hepatology (Baltimore, Md.)|November 4, 2025
AASLD/IDSA Practice Guideline on treatment of chronic hepatitis BMarc G Ghany, Calvin Q Pan, Anna S Lok, et al.
BMJ Open Gastroenterology|April 19, 2024
Progression of the FIB-4 index among patients with chronic HCV infection and early liver diseaseLisette A P Krassenburg, Raoel Maan, Amy Puenpatom, et al.
Journal of Hepatology|May 23, 2021
Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infectionGail V Matthews, Sanjay Bhagani, Marc Van der Valk, et al.
Hepatology (Baltimore, Md.)|November 7, 2021
Incidence and prediction of HBsAg seroclearance in a prospective multi-ethnic HBeAg-negative chronic hepatitis B cohortNorah A Terrault, Abdus S Wahed, Jordan J Feld, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 16, 2025
Peginterferon λ for the treatment of patients admitted to hospital with COVID-19: a phase 2, placebo-controlled randomized trialChristopher Kandel, Mia J Biondi, Mark Gillrie, et al.
Hepatology Communications|December 3, 2025
Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trialSanam Tabataba Vakili, Grishma Hirode, Atif Zahoor, et al.
The Journal of Infectious Diseases|July 21, 2021
The Inflammatory Cytokine Profile Associated With Liver Damage Is Broader and Stronger in Patients With Chronic Hepatitis B Compared to Patients With Acute Hepatitis BAlexandra Johnson Valiente, Kin Seng Liem, Kathleen B Schwarz, et al.
Journal of Viral Hepatitis|April 12, 2019
Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis BAdrian M Di Bisceglie, Wendy C King, Mauricio Lisker-Melman, et al.
Gut|November 6, 2025
HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER)Edo J Dongelmans, Lesley A Patmore, Seng Gee Lim, et al.
Journal of Hepatology|October 27, 2019
Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trialGregory J Dore, Jordan J Feld, Alex Thompson, et al.
Pageof 46